Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE

doi:10.3760/cma.j.cn371439-20230908-00036

Abstract

Abstract:

Objective To investigate the prognostic value of serum suppressor of cytokine signaling 3 （SOCS3） and thioredoxin-interacting protein （TXNIP） levels in transcatheter arterial chemoembolization （TACE） treatment of hepatocellular carcinoma （HCC）. Methods A total of 107 HCC patients who underwent TACE treatment in Wuhan Hanyang Hospital from December 2019 to July 2021 were selected as the observation objects. According to the situation after TACE treatment， the patients were divided into poor prognosis group （n=47） and good prognosis group （n=60）. Serum SOCS3 and TXNIP levels were detected by enzyme-linked immunosorbent assay， the prognostic factors were analyzed by logistic regression. The predictive value of serum SOCS3 and TXNIP levels before treatment for TACE treatment prognosis in patients with HCC was analyzed by receiver operator characteristic （ROC） curve. Results There were no statistically significant differences between good prognosis group and poor prognosis group in age （χ²=0.56， P=0.453）， gender （χ²=0.06， P=0.800）， tumor size （χ²=1.46， P=0.227）， Child-Pugh grade （χ²=0.26， P=0.608）， tumor number （χ²=0.77， P=0.382）， cirrhosis （χ²=0.03， P=0.860）， TACE times （χ²=0.16， P=0.691）， alpha-fetoprotein level before treatment （χ²=0.79， P=0.374）， and hepatitis B surface antigen （χ²=0.58， P=0.446）. The proportion of TNM stage Ⅲ patients in the poor prognosis group （57.45%， 27/47） was higher than that in the good prognosis group （25.00%， 15/60）， with a statistically significant difference （χ²=11.64， P=0.001）. The serum levels of SOCS3 and TXNIP in the good prognosis group before treatment were （114.34±20.39） and （45.64±6.41） pg/ml， respectively， while those in the poor prognosis group were （82.83±15.97） and （34.82±6.36） pg/ml， respectively， serum SOCS3 and TXNIP levels in the poor prognosis group were lower than those in the good prognosis group， with statistically significant differences （t=8.71， P<0.001； t=8.70， P<0.001）. After treatment， the serum SOCS3 and TXNIP levels in the good prognosis group were （139.65±24.32） and （64.75±7.58） pg/ml， respectively， while those in the poor prognosis group were （92.41±16.15） and （41.74±7.23） pg/ml， serum SOCS3 and TXNIP levels in the poor prognosis group were lower than those in the good prognosis group， with statistically significant differences （t=11.48， P<0.001； t=15.90， P<0.001）. Serum SOCS3 and TXNIP levels in both groups were significantly higher after treatment than before （all P<0.05）. Multivariate analysis showed that TNM stage （OR=2.53， 95%CI：1.27-5.02， P=0.008） was an independent risk factor for prognosis in HCC patients after TACE treatment， SOCS3 （OR=0.65， 95%CI：0.44-0.96， P=0.031） and TXNIP （OR=0.57， 95%CI：0.36-0.89， P=0.014） were independent protective factors for prognosis in HCC patients after TACE treatment. ROC curve analysis showed that the sensitivity and specificity of the combined detection of serum SOCS3 and TXNIP before treatment in predicting prognosis of TACE treatment in HCC patients were 81% and 92%， respectively， the area under the curve was 0.92 （95%CI：0.85-0.96）. Conclusion The low levels of serum SOCS3 and TXNIP before TACE treatment in HCC patients may indicate poor prognosis after TACE treatment. The combined detection of the two has certain predictive value for judging the prognosis of HCC patients after TACE treatment.

Key words: Carcinoma, hepatocellular, Suppressor of cytokine signaling 3 protein, Prognosis, Thioredoxin-interacting protein, Transcatheter arterial chemoembolization

Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.

Figures/Tables 4

References 22

[1]	Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1-61. DOI: 10.1016/bs.acr.2020.10.001. pmid: 33579421
[2]	Galle PR, Dufour JF, Peck-Radosavljevic M, et al. Systemic therapy of advanced hepatocellular carcinoma[J]. Future Oncol, 2021, 17(10): 1237-1251. DOI: 10.2217/fon-2020-0758. pmid: 33307782
[3]	Chang Y, Jeong SW, Young Jang J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21): 8165. DOI: 10.3390/ijms21218165.
[4]	Yan ZK, Hong S, Song YM, et al. MicroR-4449 promotes colorectal cancer cell proliferation via regulation of SOCS3 and activation of STAT3 signaling[J]. Cancer Manag Res, 2021, 13: 3029-3039. DOI: 10.2147/CMAR.S266153. pmid: 33854373
[5]	刘敏, 王阁. 原发性肝癌患者循环miR-203a-3p表达水平与SOCS1和SOCS3的关系及意义[J]. 中国免疫学杂志, 2020, 36(7): 848-851, 858. DOI: 10.3969/j.issn.1000-484X.2020.07.016.
[6]	Chen YT, Ning JL, Cao WJ, et al. Research progress of TXNIP as a tumor suppressor gene participating in the metabolic reprogramming and oxidative stress of cancer cells in various cancers[J]. Front Oncol, 2020, 10: 568574. DOI: 10.3389/fonc.2020.568574.
[7]	Yamaguchi F, Hirata Y, Akram H, et al. Editorial expression of concern: FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801[J]. BMC Cancer, 2022, 22(1): 665. DOI: 10.1186/s12885-022-09764-1. pmid: 35715788
[8]	Singh J, Sah B, Shen Y, et al. Histone methyltransferase inhibitor UNC0642 promotes breast cancer cell death by upregulating TXNIP-dependent oxidative stress[J]. Chem Biol Interact, 2023, 385: 110720. DOI: 10.1016/j.cbi.2023.110720.
[9]	Xie M, Xie RY, Xie S, et al. Thioredoxin interacting protein (TXNIP) acts as a tumor suppressor in human prostate cancer[J]. Cell Biol Int, 2020, 44(10): 2094-2106. DOI: 10.1002/cbin.11418.
[10]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19(1): 1-20. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.001.
[11]	Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma[J]. J Family Med Prim Care, 2021, 10(10): 3553-3560. DOI: 10.4103/jfmpc.jfmpc_2347_20. pmid: 34934646
[12]	Xiao YY, Li Y, Shi DN, et al. MEX3C-mediated decay of SOCS3 mRNA promotes JAK2/STAT3 signaling to facilitate metastasis in hepatocellular carcinoma[J]. Cancer Res, 2022, 82(22): 4191-4205. DOI: 10.1158/0008-5472.CAN-22-1203. pmid: 36112698
[13]	Chen LX, Huang XX, Zhang WZ, et al. Correlation of PD-L1 and SOCS3 co-expression with the prognosis of hepatocellular carcinoma patients[J]. J Cancer, 2020, 11(18): 5440-5448. DOI: 10.7150/jca.46158. pmid: 32742491
[14]	Liu ZK, Li C, Zhang RY, et al. EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling[J]. Mol Cancer, 2021, 20(1): 79. DOI: 10.1186/s12943-021-01377-9.
[15]	Yang Y, Mao FF, Guo L, et al. Tumor cells derived-extracellular vesicles transfer miR-3129 to promote hepatocellular carcinoma metastasis by targeting TXNIP[J]. Dig Liver Dis, 2021, 53(4): 474-485. DOI: 10.1016/j.dld.2021.01.003.
[16]	Cho SY, Kim S, Son MJ, et al. Clinical significance of the thioredoxin system and thioredoxin-domain-containing protein family in hepatocellular carcinoma[J]. Dig Dis Sci, 2019, 64(1): 123-136. DOI: 10.1007/s10620-018-5307-x.
[17]	Toh TB, Lim JJ, Hooi L, et al. Targeting JAK/STAT pathway as a therapeutic strategy against SP/CD44⁺ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma[J]. J Hepatol, 2020, 72(1): 104-118. DOI: 10.1016/j.jhep.2019.08.035.
[18]	Chen YT, Feng XP, Yuan YH, et al. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage[J]. Cell Death Dis, 2022, 13(4): 338. DOI: 10.1038/s41419-022-04783-z. pmid: 35414060
[19]	谭骅, 仁虹, 赵玲, 等. 行TACE治疗后原发性肝细胞癌患者预后的影响因素[J]. 昆明医科大学学报, 2019, 40(3): 29-34. DOI: 10.3969/j.issn.1003-4706.2019.03.006.
[20]	廖玉波, 赵妍, 胡鸿涛, 等. 肝动脉化疗栓塞术治疗原发性肝细胞癌预后影响因素分析[J]. 中国介入影像与治疗学, 2017, 14(12): 729-733. DOI: 10.13929/j.1672-8475.201704027.
[21]	Jiang BG, Wang N, Huang J, et al. Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients[J]. Oncotarget, 2017, 8(17): 28621-28627. DOI: 10.18632/oncotarget.16157.
[22]	赵灵利, 王磊, 张裕, 等. 血清γ-谷氨酰转肽酶及甲胎蛋白对肝动脉化疗栓塞术治疗原发性肝癌患者预后的影响[J]. 临床误诊误治, 2022, 35(6): 59-63. DOI: 10.3969/j.issn.1002-3429.2022.06.014.

项目	例数	预后不良组（n=47）	预后良好组（n=60）	χ²值	P值
年龄（岁）
<60	43	17（36.17）	26（43.33）	0.56	0.453
≥60	64	30（63.83）	34（56.67）	0.56	0.453
性别
男	83	37（78.72）	46（76.67）	0.06	0.800
女	24	10（21.28）	14（23.33）	0.06	0.800
肿瘤大小（mm）
<50	48	18（38.30）	30（50.00）	1.46	0.227
≥50	59	29（61.70）	30（50.00）	1.46	0.227
Child-Pugh分级
A级	70	32（68.09）	38（63.33）	0.26	0.608
B级	37	15（31.91）	22（36.67）	0.26	0.608
TNM分期
Ⅰ~Ⅱ	65	20（42.55）	45（75.00）	11.64	0.001
Ⅲ	42	27（57.45）	15（25.00）	11.64	0.001
肿瘤数量（个）
1	75	35（74.47）	40（66.67）	0.77	0.382
>1	32	12（25.53）	20（33.33）	0.77	0.382
肝硬化
有	88	39（82.98）	49（81.67）	0.03	0.860
无	19	8（17.02）	11（18.33）	0.03	0.860
TACE次数（次）
1	41	19（40.43）	22（36.67）	0.16	0.691
≥2	66	28（59.57）	38（63.33）	0.16	0.691
治疗前AFP水平（ng/ml）
<400	53	21（44.68）	32（53.33）	0.79	0.374
≥400	54	26（55.32）	28（46.67）	0.79	0.374
乙型肝炎病毒表面抗原
阳性	78	36（76.60）	42（70.00）	0.58	0.446
阴性	29	11（23.40）	18（30.00）	0.58	0.446

影响因素	β值	标准误	Waldχ²值	OR值	95%CI	P值
TNM分期	0.93	0.35	7.03	2.53	1.27~5.02	0.008
SOCS3	-0.43	0.20	4.64	0.65	0.44~0.96	0.031
TXNIP	-0.56	0.23	5.97	0.57	0.36~0.89	0.014